Cohance Lifesciences 
Dealstreet

SAM acts on Cohance Lifesciences ₹3,093 on-market share sale

The transaction team was led by Ambarish.

Bar & Bench

Shardul Amarchand Mangaldas & Co has acted as the legal advisor for an on-market sale of 8.93% shareholding in Cohance Lifesciences Limited for ₹3,093 crore by Jusmiral Holdings Limited.

The transaction team was led by Ambarish (Partner), with support from Krishaal Morjaria (Principal Associate) and Varun Natarajan (Senior Associate).

Kanwardeep Singh Kapany (Counsel) advised on Securities law aspects.

Ameya Gokhale (Partner) and Kriti Kalyani (Principal Associate) also provided inputs.

Ambarish

SAM has earlier advised Advent in its control acquisition of Suven Pharmaceuticals Limited by way of a share purchase and mandatory open offer. SAM also advised on the subsequent merger of Cohance with and into Suven, upon which Suven was renamed as Cohance. 

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Also Read

“If you cry, I will cry”: Justice Tara Vitasta Ganju to daughter during Delhi High Court farewell speech

Supreme Court sets aside MP High Court order stipulating 'tree planting' as condition to grant bail to murder convicts

Supreme Court directs Centre, States to complete appointment of Information Commissioners within 3 weeks

Delhi High Court asks police for report on rape, forced beef-eating allegations against journalist Omar Rashid

Supreme Court grants bail to three accused in Sambhal mosque violence case

SCROLL FOR NEXT